Bioreagents | Bioprocessing Reagents

Bioreagents Products | Bioprocessing Reagents

Review our selection of Bioprocessing reagents. Download the specifications to learn more about each.

DTT Dithiothreitol

Industry-leading quality and reliability (Purity ≥ 99%). Reagent used for maintaining thiol groups in a reduced state during protein processing, isolation, and denaturing. Incorporated into some leading COVID-19 testing kits.
View Specifications

DTT Dithiothreitol – Molecular Biology Grade

Premium MBG grade. Includes additional testing for: Protease, Rnase, Dnase, ICP metals.

Download Specifications

DTT Dithiothreitol – cGMP

Premium cGMP grade. Includes additional testing: Residual solvents.



Download Specifications

DTE Dithioerythritol

Reagent used for maintaining thiol groups in a reduced state during protein processing, isolation, and denaturing Purity ≥ 99%.
Download Specifications

DHAA Dehydroascorbic acid – cGMP

Premium cGMP grade. Reagent used in the oxidation of proteins and prep of ADC’s.
Download Specifications

TCEP Tris (2-carboxyethyl) phosphine, hydrochloride – cGMP

Premium cGMP grade. Reagent used in the reduction of disulfide bonds and during prep of ADC’s.
Download Specifications

IPTG Isopropyl-β-D-Thiogalactopyranoside, Non-Animal Origin

Industry-leading quality and reliability (Purity ≥ 99%). Reagent used for maintaining thiol groups in a reduced state during protein processing, isolation, and denaturing. Incorporated into some leading COVID-19 testing kits.
Download Specifications

EDAC 1-(3-Dimethylaminopropyl)-3-Ethylcarbodiimide HCI

Water soluble cross-linker used to conjugate proteins and peptides.
Download Specifications

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors